A retrospective study has been carried out with data from 11,000 patients to train artificial intelligence algorithms and adapt the Nora mobile application to different patient profiles.

Transaction expands Formation Bio's immunology pipeline with Phase 1 ready drug candidate.

The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB) with the participation of VHIR.

The aim of the initiative is to improve the management of innovation projects and their reach to patients and promote innovative and entrepreneurial culture.

This certification pushes our system towards a more mature model, with defined processes, clear metrics and a real focus on impact.

The report by the Botin Foundation and Inveniam places the Institute only behind the CSIC and the UB.

This is a structured system that prioritizes projects with the greatest potential to ensure their viability and maximize the chances of success in their clinical application and commercialization, with a focus on benefiting patients.

A key initiative that connects researchers with a network of more than 20 external mentors who are experts in various fields within the ecosystem.

The Parc Taulí and Vall d’Hebron spin-off has raised €2.77 million in private and public funds, enabling it to complete the necessary clinical trials to obtain CE marking and bring this device to market.

Hybrids VITA, developed together with Medical Simulator, reproduces different clinical scenarios for training on how to prevent, diagnose and treat possible complications of ECMO, which is a very complex technique.

The device, called Winco USG, is a simulation platform for holistic and integrated training of professionals performing this type of procedure.

The Biomedical Research in Cancer Stem Cells group at VHIR has identified a new therapeutic target and is working to find new therapies for this type of tumor.

VHIR organises the first meeting between entrepreneurs and the investment ecosystem.

A clinical trial with the prototype of the device shows that the use of this technology improves patient monitoring by nurses and reduces post-surgical complications.

The second Joan Roget Awards for Knowledge Transfer acknowledged three success stories in the Catalan research system, including the VHIR for the creation of its own innovation model.

The product is now in the last stage of prototyping and will move to the verification and validation stages thanks to current fundraising.

This investment from EIT Health in the project will enable D-Sight to progress in the clinical development of its groundbreaking treatment for the early stages of diabetic retinopathy.

This collaboration solidifies their co-ownership of the patent application for "markers for the diagnosis of large vessel occlusion"

After carrying out a first feasibility trial in collaboration with the Assisted Reproduction Section of the Vall d'Hebron Hospital, Manina Medtech is moving towards a pilot trial in IVF patients.

This initiative of the ”la Caixa” Foundation offers the selected entrepreneurial scientists financial support and support through individual mentoring and training.

The head of the Rheumatology Service at Vall d'Hebron University Hospital and of the Rheumatology research group at VHIR is a highly accomplished rheumatologist with a distinguished career in the field.

Femtech is a spin-off of the Vall d'Hebron Research Institute (VHIR) and is part of the accelerator BCN Health Booster of the Barcelona Science Park

YSOTOPE, a DeepTech start-up with the mission to improve the use of immunotherapies through medical imaging, became part of the spin-off network of VHIR and successfully closed its first investment round of €150,000 with Biozell Ventures.

The start-up Tesai Care works in developing Heecap, a non-invasive electrostimulation system to avoid atrophy to the muscles of respiration in patients on mechanical ventilation in ICUs.